Poupot Mary, Boissard Frédéric, Betous Delphine, Bardouillet Laure, Fruchon Séverine, L'Faqihi-Olive Fatima, Pont Frédéric, Mekaouche Mourad, Ingoure Sophie, Sicard Hélène, Dubreuilh Guy, Fournié Jean-Jacques
INSERM UMR1037-Cancer Research Center of Toulouse, CHU Purpan, F-31300, Toulouse, France,
Cell Mol Biol Lett. 2014 Dec;19(4):649-58. doi: 10.2478/s11658-014-0218-0. Epub 2014 Nov 25.
Phosphoantigens (PAgs) activate Vγ9Vδ2 T lymphocytes, inducing their potent and rapid response in vitro and in vivo. However, humans and nonhuman primates that receive repeated injections of PAgs progressively lose their Vγ9Vδ2 T cell response to them. To elucidate the molecular mechanisms of this in vivo desensitization, we analyzed the transcriptome of circulating Vγ9Vδ2 T cells from macaques injected with PAg. We showed that three PAg injections induced the activation of the PPARα pathway in Vγ9Vδ2 T cells. Thus, we analyzed the in vitro response of Vγ9Vδ2 T cells stimulated with a PPARα agonist. We demonstrated that in vitro PPARα pathway activation led to the inhibition of the BrHPP-induced activation and proliferation of human Vγ9Vδ2 T cells. Since the PPARα pathway is involved in the antigen-selective desensitization of human Vγ9Vδ2 T cells, the use of PPARα inhibitors could enhance cancer immunotherapy based on Vγ9Vδ2 T cells.
磷酸化抗原(PAgs)可激活Vγ9Vδ2 T淋巴细胞,使其在体外和体内产生强大而快速的反应。然而,接受重复注射PAgs的人类和非人类灵长类动物对它们的Vγ9Vδ2 T细胞反应会逐渐丧失。为了阐明这种体内脱敏的分子机制,我们分析了注射PAg的猕猴循环Vγ9Vδ2 T细胞的转录组。我们发现,三次PAg注射可诱导Vγ9Vδ2 T细胞中PPARα途径的激活。因此,我们分析了用PPARα激动剂刺激的Vγ9Vδ2 T细胞的体外反应。我们证明,体外PPARα途径的激活导致对BrHPP诱导的人Vγ9Vδ2 T细胞激活和增殖的抑制。由于PPARα途径参与了人Vγ9Vδ2 T细胞的抗原选择性脱敏,使用PPARα抑制剂可能会增强基于Vγ9Vδ2 T细胞的癌症免疫治疗。